Nicollet Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.48M Sell
19,646
-877
-4% -$69.2K 0.51% 47
2025
Q4
$1.62M Buy
20,523
+115
+0.6% +$8.66K 0.51% 45
2025
Q3
$1.33M Sell
20,408
-339
-2% -$16.6K 0.44% 46
2025
Q2
$820K Sell
20,747
-704
-3% -$23K 0.27% 55
2025
Q1
$647K Buy
21,451
+1,665
+8% +$54.5K 0.23% 61
2024
Q4
$692K Sell
19,786
-616
-3% -$23K 0.24% 56
2024
Q3
$817K Buy
20,402
+294
+1% +$13.7K 0.28% 53
2024
Q2
$958K Sell
20,108
-413
-2% -$16.9K 0.36% 47
2024
Q1
$890K Buy
20,521
+10,745
+110% +$512K 0.33% 53
2023
Q4
$495K Buy
9,776
+1,108
+13% +$53.1K 0.2% 55
2023
Q3
$393K Sell
8,668
-90
-1% -$3.71K 0.18% 55
2023
Q2
$359K Buy
8,758
+293
+3% +$11.3K 0.16% 56
2023
Q1
$303K Buy
8,465
+527
+7% +$19.8K 0.16% 55
2022
Q4
$300K Sell
7,938
-570
-7% -$24K 0.17% 55
2022
Q3
$376K Buy
8,508
+66
+0.8% +$2.78K 0.21% 51
2022
Q2
$313K Buy
8,442
+173
+2% +$6.52K 0.17% 52
2022
Q1
$306K Sell
8,269
-235
-3% -$7.69K 0.14% 55
2021
Q4
$259K Sell
8,504
-1,997
-19% -$62.9K 0.1% 58
2021
Q3
$352K Sell
10,501
-3
-0% -$113 0.15% 56
2021
Q2
$419K Sell
10,504
-307
-3% -$12K 0.17% 60
2021
Q1
$486K Sell
10,811
-58
-0.5% -$3.23K 0.21% 58
2020
Q4
$615K Buy
10,869
+508
+5% +$25.3K 0.28% 52
2020
Q3
$492K Sell
10,361
-29
-0.3% -$1.61K 0.25% 50
2020
Q2
$613K Buy
10,390
+385
+4% +$21.4K 0.34% 48
2020
Q1
$473K Sell
10,005
-335
-3% -$18.7K 0.35% 49
2019
Q4
$625 Sell
10,340
-290
-3% -$17.3K 0.29% 55
2019
Q3
$637K Buy
10,630
+75
+0.7% +$4.89K 0.4% 54
2019
Q2
$678K Sell
10,555
-70
-0.7% -$4.95K 0.43% 49
2019
Q1
$862K Buy
10,625
+30
+0.3% +$1.94K 0.57% 48
2018
Q4
$573K Sell
10,595
-95
-0.9% -$4.84K 0.45% 52
2018
Q3
$551K Buy
10,690
+435
+4% +$20.4K 0.36% 61
2018
Q2
$427K Buy
10,255
+330
+3% +$14.6K 0.31% 61
2018
Q1
$437K Buy
9,925
+30
+0.3% +$1.52K 0.34% 61
2017
Q4
$498K Buy
+9,895
New +$543K 0.41% 59

Other funds holding IONS

Nicollet Investment Management's IONS Position: Q1 2026 in Review

Nicollet Investment Management reduced its Ionis Pharmaceuticals (IONS) stake by 4.3% in Q1 2026, selling an estimated $69.2K and leaving 19,646 shares worth $1.48M. The position accounts for 0.51% of the portfolio, ranked #47.

Nicollet Investment Management first reported a position in IONS in Q4 2017 and has held it in 34 quarters since. The position peaked at $1.62M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Nicollet Investment Management held 19,646 shares of Ionis Pharmaceuticals worth $1.48M as of Q1 2026.
  • Nicollet Investment Management sold 877 Ionis Pharmaceuticals shares in Q1 2026, an estimated $69.2K.
  • Ionis Pharmaceuticals made up 0.51% of Nicollet Investment Management's portfolio in Q1 2026, its #47 holding.
  • Nicollet Investment Management first reported a position in Ionis Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • Nicollet Investment Management's Ionis Pharmaceuticals position peaked at $1.62M in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Nicollet Investment Management's 13F filing for Q1 2026, filed 13 May 2026.